drugset / Trial / NCT01810952

The Management of Glucocorticoid-Induced Hyperglycemia in Hospitalized Patients

NCT01810952

Phase 4 Completed 37 enrolled Baylor College of Medicine
RandomizedParallel-groupOpen-labelTreatment

Summary

The investigators hypothesize that includes patient weight and glucocorticoid dose can be used to safely initiate insulin treatment in diabetic/hyperglycemic patients who are to be treated with pharmacological doses of glucocorticoids.

Timeline

Start
2010-09
Primary completion
2013-09
Completion
2013-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Insulin Protein / enzyme biologic 0.1 iu/kg
Subject Insulin Protein / enzyme biologic 0.4 iu/kg
Background Insulin Lispro Protein / enzyme biologic 0.1 iu/kg
Background Insulin Lispro Protein / enzyme biologic 0.2 iu/kg
Background Insulin Lispro Protein / enzyme biologic 0.4 iu/kg
Background insulin glargine Protein / enzyme biologic 0.2 iu/kg